查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1791210

Biktarvy 市场报告：2031 年趋势、预测与竞争分析

Biktarvy Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球Biktarvy市场前景光明，医院和零售药局市场都蕴藏着巨大的机会。预计2025年至2031年期间，全球Biktarvy市场的复合年增长率将达到2.7%。推动该市场发展的关键因素包括爱滋病毒/爱滋病盛行率的上升、认知度的提升和筛检计画的推进，以及对单一药物疗法的日益偏好。

  • Lucintel 预测，按类型学名药在预测期内将出现高速成长。
  • 从应用程式来看，零售药局预计将实现高速成长。
  • 按地区划分，预计北美将在预测期内实现最高成长。

一份全面的 150 多页报告提供了宝贵的见解，为您的业务决策提供参考。

Biktarvy市场的新趋势

Biktarvy 市场强劲，但并非一成不变。一些关键趋势正在涌现，这些趋势将决定其未来发展方向以及在整个 HIV 治疗领域中的地位。这些趋势包括：长效注射剂的研发和广泛应用、对合併症患者治疗的重视程度不断提高、暴露前预防 (PrEP) 的推广应用、单药治疗方案的持续重要性，以及专利到期和学名药竞争的潜在影响。了解这些趋势对于预测未来市场趋势至关重要。

  • 长效注射疗法：包括卡博特韦和利匹韦林（Cabenuva）在内的长效注射抗逆转录病毒疗法的开发和使用日益增多，是爱滋病治疗领域的一大趋势。这些治疗方法的优点在于给药频率较低（例如每月或每两个月一次），从而可以最大限度地减少锭剂负担，从而提高患者的依从性和满意度。虽然比克托维（Biktarvy）是一种简单的每日一次口服方案，但较低的给药频率可能对部分患者俱有吸引力，并可能长期影响比克托维的市场占有率。
  • 更重视合併症患者的治疗：HIV 感染者通常患有併发症，包括心血管疾病、肾功能受损和骨骼健康受损。因此，我们需要一种不仅能有效抑制病毒，而且安全且耐受性良好的 HIV 治疗药物，并考虑到这些合併症。目前正在进行的研究和临床试验正在探索 Biktarvy 对老年患者和合併症患者的长期数据，这凸显了满足这些复杂患者需求的重要性。
  • 暴露前预防的扩展：虽然Biktarvy本身尚未核准作为PrEP，但对HIV预防方案的日益关注以及PrEP使用的扩大将影响整个HIV市场的规模。 PrEP在预防HIV新兴感染的有效性，反过来可能影响未来治疗市场的规模。 Biktarvy的生产商吉利德公司凭藉Decoy等其他药物在PrEP市场占有一席之地，这表明该公司在治疗和预防方面拥有更广泛的战略利益。新型长效PrEP的推出可能会进一步改变这个局面。
  • 锭剂疗法的持续优势：Biktarvy 等单片疗法因其简单易用且更易于坚持，已成为大多数 HIV 感染者的标准治疗方法方案。每日只需服用一片，方便快捷，使治疗更轻鬆，并带来更佳疗效。 Biktarvy 的成功源自于其小剂量但有效且安全性可耐受的单片疗法 (STR)。这一趋势意味着单片疗法将保持显着的市场份额，但它们将面临来自更新、长效产品的竞争。
  • 专利到期和学名药竞争的潜在影响：虽然Biktarvy目前受专利保护，但专利最终将到期，使其容易受到学名药。学名药抗逆转录病毒药物有可能大幅降低治疗成本，并衝击Biktarvy等品牌药的市场占有率和收益。吉利德必须为未来的竞争做好准备，并开发新的创新HIV治疗方案，以维持其市场主导地位。

所有这些新兴趋势正在共同重塑Biktarvy市场。儘管Biktarvy目前作为单药疗法占据领先地位，但它必须适应长效注射剂日益普及以及对合併症患者治疗日益增长的重视。 PrEP的成长可能会影响该疗法的整体市场规模，而学名药的上市最终将给公司带来价格压力。吉利德的创新和治疗开发能力将是驾驭这些不断变化的市场动态并保持其在HIV治疗领域强势地位的关键。

Biktarvy市场的最新趋势

目前围绕Biktarvy市场的动态旨在巩固其作为一线HIV治疗药物的领导地位。这些动态包括：推出长期疗效和安全性数据；研究其在包括合併感染者在内的各类患者群体中的应用；以及评估旨在提升患者便利性和改善治疗效果的新剂型。所有这些倡议都旨在扩大Biktarvy的用途，并巩固其在新兴HIV治疗领域的地位。

  • 长期疗效和安全性数据：正在进行的临床和真实世界研究正在提供关于Biktarvy疗效和安全性的长期数据。在包括逆转录病毒和机会性感染疾病会议 (CROI) 在内的主要科学会议上，报告通常显示，Biktarvy治疗患者的多年结果显示其具有持久的病毒抑制效果和良好的安全性，支持Biktarvy作为一种稳定的长期治疗选择。
  • 特定患者群体研究：目前正在进行研究，评估比克托丙酸 (Biktarvy) 在特定 HIV 感染者亚群中的有效性和安全性。这些研究涵盖初治患者、从其他抗逆转录病毒病毒疗法转换的患者、老年人以及合併症患者（例如乙肝病毒 (HBV) 合併感染）。这些研究结果将有助于指南治疗，并扩大对比克托丙酸对更广泛患者群体的价值的认知。例如，已证实在 HIV/HBV 合併感染患者中，转换至比克托丙酸后病毒抑制率较高。
  • 考虑新的配方和给药方法：Biktarvy 目前为每日一次的口服锭剂；然而，HIV 治疗领域正在积极研究长效配方。虽然短期内并非仅针对 Biktarvy，但药物输送系统的技术进步可能会导致未来对 Biktarvy 或其各个成分进行重新配方，以进一步提高便利性和依从性。
  • 与其他抗逆转录病毒疗法相比的相对疗效和安全性研究：为了进一步明确Biktarvy在治疗领域的地位，我们正在临床试验中将其与其他广泛使用的抗逆转录病毒疗法进行比较。这些临床试验评估了Biktarvy的疗效、安全性和耐受性，以帮助临床医生做出明智的治疗决策。这些疗效和安全性比较研究的正面结果支持将Biktarvy推荐为第一线治疗方案。
  • 收集真实世界证据 在受控临床试验之外，收集和分析真实世界证据正变得越来越重要。这些研究透过确定Biktarvy在临床试验罕见方案条件之外的异质性患者群体中的疗效和耐受性，来评估其在真实世界条件下的效果。真实世界证据可用于补充临床试验讯息，并进一步有助于制定治疗建议。

这些最新进展凸显了Biktarvy在HIV管理中最大化应用的持续努力。不断累积的纵向数据、特殊人群研究以及HIV治疗研究的总体趋势，都有助于更好地理解Biktarvy在改善HIV感染者生活方面的地位和前景。这些进展进一步证明了Biktarvy在现代HIV治疗时代的关键作用。

目录

第一章执行摘要

第二章 市场概述

  • 背景和分类
  • 供应链

第三章：市场趋势与预测分析

  • 宏观经济趋势与预测
  • 产业驱动力与挑战
  • PESTLE分析
  • 专利分析
  • 法规环境

第四章 全球 Biktarvy 市场（按类型）

  • 概述
  • 按类型进行吸引力分析
  • 原始药物：趋势与预测（2019-2031）
  • 学名药：趋势与预测（2019-2031）

第五章 全球 Biktarvy 市场（按应用）

  • 概述
  • 按用途进行吸引力分析
  • 医院：趋势与预测（2019-2031）
  • 零售药局：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031）

第六章区域分析

  • 概述
  • 全球 Biktarvy 市场（按地区）

第七章 北美 Biktarvy 市场

  • 概述
  • 北美 Biktarvy 市场（按类型）
  • 北美 Biktarvy 市场（按应用）
  • Biktarvy 在美国的市场
  • 墨西哥的Biktarby市场
  • 加拿大 Biktarbi 市场

第八章 欧洲 Biktarvy 市场

  • 概述
  • 欧洲 Biktarvy 市场类型
  • 欧洲 Biktarvy 市场（按应用）
  • 德国 Biktarby 市场
  • 法国的Biktarbi市场
  • 西班牙的Biktarbi市场
  • 义大利 Biktarbi 市场
  • 英国Biktarvy 市场

9. 亚太地区 Biktarvy 市场

  • 概述
  • 亚太地区 Biktarvy 市场类型
  • 亚太地区 Biktarvy 市场（按应用）
  • 日本的Biktarvy市场
  • 印度的Biktarbi市场
  • 中国的Biktarvy市场
  • 韩国的Biktarbi市场
  • 印尼的Biktarbi市场

第十章 其他地区的 Biktarbi 市场

  • 概述
  • 其他地区 Biktarbi 市场（按类型）
  • 世界其他地区 Biktarbi 市场（按应用）
  • 中东的Biktarbi市场
  • 南美的 Biktarvy 市场
  • 非洲 Biktarbi 市场

第十一章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析
    • 竞争对手之间的竞争
    • 买方的议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 新进入者的威胁
  • 市场占有率分析

第十二章机会与策略分析

  • 价值链分析
  • 成长机会分析
    • 按类型分類的成长机会
    • 按应用分類的成长机会
  • 全球 Biktarvy 市场的新趋势
  • 战略分析
    • 新产品开发
    • 认证和许可
    • 合併、收购、协议、合作和合资企业

第十三章：价值链主要企业的公司简介

  • 竞争分析
  • Gilead Sciences
  • ABACUS MEDICINE
  • Hetero Drugs
  • Gador
  • BMODESTO

第十四章 附录

  • List of Figures
  • List of Tables
  • Research Methodology
  • Disclaimer
  • Copyright
  • Abbreviations and Technical Units
  • About Us
  • Contact Us

The future of the global Biktarvy market looks promising with opportunities in the hospital and retail pharmacy markets. The global Biktarvy market is expected to grow with a CAGR of 2.7% from 2025 to 2031. The major drivers for this market are the rising prevalence of HIV/AIDS, the growing awareness & screening programs, and the increasing preference for single-tablet regimens.

  • Lucintel forecasts that, within the type category, generic drugs are expected to witness higher growth over the forecast period.
  • Within the application category, retail pharmacy is expected to witness higher growth.
  • In terms of region, North America is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Biktarvy Market

The Biktarvy market, as strong as it is, is not fixed. A number of very important trends are emerging that will shape its future direction and position within the overall HIV treatment environment. Some of these trends involve the creation and uptake of long-acting injectable treatments, the growing emphasis on the treatment of patients with comorbidities, the growing use of pre-exposure prophylaxis (PrEP), the continued relevance of single-tablet regimens, and the possible influence of patent losses and generic competition. Knowledge of these trends is essential to forecast future market trends.

  • Long-Acting Injectable Therapies: Development and increasing use of long-acting injectable antiretroviral therapies, including cabotegravir and rilpivirine (Cabenuva), are a major trend in HIV therapy. These treatments bring the benefit of less frequent dosing (e.g., monthly or bi-monthly), which can simplify patient adherence and patient satisfaction by minimizing the pill burden. Whereas Biktarvy is a simple once-daily oral regimen, the attractiveness of even less-frequent dosing will appeal to some patients and could affect Biktarvy's market share over the long term.
  • Increased Emphasis on Treating Patients with Comorbidities: Individuals with HIV are increasingly having comorbidities like cardiovascular disease, renal impairment, and bone health disorders. This requires HIV therapies that are not only efficacious in viral suppression but also safe and well-tolerated in the context of these other comorbidities. Long-term data on Biktarvy among older patients and those with comorbidities are being studied in ongoing research and clinical trials, which underscores the relevance of meeting these complicated patient requirements in the market.
  • Pre-Exposure Prophylaxis Expansion: Although Biktarvy itself is not approved for PrEP, the increasing focus on HIV prevention regimens and the growth in PrEP use impact the size of the overall HIV market. The effectiveness of PrEP in preventing new HIV infections can, in turn, affect the size of the treatment market in the future. Gilead, the company that makes Biktarvy, also has a presence in the market for PrEP with other medications such as Decoy, suggesting a more general strategic interest in both treatment and prevention. The introduction of new, long-acting PrEP forms may further shift the scene.
  • Ongoing Supremacy of Single-Tablet Regimens: Single-tablet regimens such as Biktarvy have become the standard of care for most individuals with HIV because they are simple and encourage improved adherence. The ease of taking only a single pill a day makes the treatment easier and can result in better outcomes. Biktarvy's success derives in part from its position as a small but effective STR that has a well-tolerated safety profile. This trend lines up with that STRs will maintain a very large share of the market though they will get competition from some new long-acting products on the horizon.
  • Potential Effect of Patent Expirations and Generic Competition: Although Biktarvy is now under patent protection, the eventual lapse of these patents will allow generic competition. Generic forms of antiretroviral drugs can dramatically reduce the cost of treatment, potentially affecting the market share and revenue of branded medications such as Biktarvy. Gilead must be planning for this future competition by creating new and innovative HIV treatments in order to preserve its market dominance.

These new trends are all combined to reshape the Biktarvy market. Although Biktarvy's current status as a top single-tablet regimen is robust, it will have to adjust to the growing availability of long-acting injectables and the expanding emphasis on treating patients with comorbidities. The growth of PrEP may impact the total treatment market size, and the eventual launch of generics will bring pricing pressures. Gilead's innovative capacity and therapeutic development capabilities will be key in navigating these shifting market dynamics and keeping a solid footing in the HIV treatment space.

Recent Developments in the Biktarvy Market

Current events surrounding the Biktarvy market are focused on affirming its leadership as a first-line HIV treatment. These events include the introduction of long-term efficacy and safety data, studies of its application in varied patient populations such as those with co-infections, and evaluation of new formulations to improve patient convenience and outcomes. All these are aimed at expanding Biktarvy's use and affirming its place in the emerging HIV treatment landscape.

  • Long-Term Efficacy and Safety Data: Ongoing clinical trials and real-world studies continue to generate long-term data on the efficacy and safety of Biktarvy. Presentations at key conferences, including the Conference on Retroviruses and Opportunistic Infections (CROI), typically include multi-year outcomes showing durable viral suppression and a good safety profile in patients receiving Biktarvy. This supports confidence in Biktarvy as a stable long-term treatment option.
  • Studies in Specific Patient Populations: Research is being conducted to evaluate the effectiveness and safety of Biktarvy in specific subgroups of people living with HIV. This includes studies in treatment-naive individuals, those switching from other antiretroviral regimens, older adults, and individuals with comorbidities such as hepatitis B virus (HBV) co-infection. Findings from these studies assist in guiding treatment and broadening the knowledge of Biktarvy's value to a wider group of patients. For instance, high viral suppression rates have been demonstrated in patients with HIV/HBV co-infection switching to Biktarvy.
  • Investigation of New Formulations and Delivery Options: Although Biktarvy is presently marketed as a once-daily oral tablet, there is active research across the overall HIV therapy space for long-acting formulations. Although nonspecific to Biktarvy in the short run, technology advances in drug delivery systems could in the future create reformulated versions of Biktarvy or its individual elements with the goal of further enhancing convenience and adherence.
  • Relative Efficacy and Safety Studies Compared to Other Antiretroviral Regimens: Further to define its position in therapy, Biktarvy has been compared to other widely used regimens of antiretroviral therapy through clinical trials. Relative efficacy, safety, and tolerability are all evaluated in such studies, which serve to help clinicians make informed treatment decisions. Favorable results from these relative efficacy and safety studies endorse Biktarvy as a preferred first-line treatment.
  • Collection of Real-World Evidence: Outside of controlled clinical trials, collection and analysis of real-world evidence are becoming more critical. These trials assess how Biktarvy works under real-world clinical practice conditions, revealing its efficacy and tolerability in a heterogeneous group of patients outside the rare protocol conditions of clinical trials. Real-world evidence can be used to supplement clinical trial information and contribute further to treatment recommendations.

These recent advances collectively emphasize the continued efforts to maximize the utilization of Biktarvy in HIV management. The accumulation of long-term data, research in special populations, and the general trends in HIV treatment research are all leading to a better understanding of Biktarvy's place and promise in enhancing the lives of individuals living with HIV. These advances serve to further establish Biktarvy as an integral part of the contemporary HIV treatment era.

Strategic Growth Opportunities in the Biktarvy Market

Strategic growth areas for Biktarvy are to build on its proven efficacy and safety profile to expand its use across various stages of HIV treatment. These areas are to consolidate its role in first-line treatment, emerge as the first choice among those switching treatment regimens, increase its use in patients with co-infections, and look into new formulations to make it more convenient for patients and improve adherence. Building on these areas can further enhance Biktarvy's market presence.

  • Initial Therapy for Naive Patients: Biktarvy has already made a significant name for itself as an initial therapy for newly diagnosed HIV individuals. Its ability to provide fast and sustained viral suppression, combined with its tolerability profile and single-tablet once-daily regimen, makes it an appealing choice for initial therapy. Ongoing efforts towards educating healthcare professionals and newly diagnosed patients about these advantages can further establish its place in this critical use.
  • Switch Therapy for Virologically Suppressed Patients: For patients who are already virologically suppressed on alternative antiretroviral regimens but perhaps having issues with tolerability, drug interactions, or pill burden, Biktarvy represents a streamlined and frequently better-tolerated option. Emphasizing Biktarvy as an exemplary switching option through clinical evidence illustrating superior outcomes or patient satisfaction can increase growth in this category.
  • HIV/HBV Co-infected Individuals Treatment: HIV patients usually present with co-infections, and one such common co-infection is hepatitis B. Biktarvy's efficacy in suppressing both HIV and HBV has been shown in studies, which makes it an important choice for this particular patient group. Increased research and education among healthcare providers who treat co-infected patients can increase Biktarvy's application in this important use.
  • Long-Acting Formulations Development: Although Biktarvy is already an oral tablet, the direction of long-acting injectable HIV treatments represents a future growth possibility. Gilead's knowledge in developing HIV drugs could be used to develop long-acting versions of Biktarvy or its active ingredients, providing improved convenience and adherence for those who want to take less medication more infrequently.
  • Pediatric and Adolescent Use: Another opportunity for growth is extending the approved indication of Biktarvy to younger age groups, such as pediatric and adolescent patients. Clinical trials assessing the safety and efficacy of Biktarvy in these patient groups, with subsequent regulatory approvals, can extend its use and offer effective treatment to children and adolescents with HIV.

These strategic growth prospects, from establishing its place in first-line treatment to investigating new forms and broadening its application in certain patient populations, have the potential to greatly affect the Biktarvy market. By targeting these, Gilead is able to further build on the asset strengths of Biktarvy to meet the changing needs of individuals living with HIV while solidifying its leadership in the antiretroviral category.

Biktarvy Market Driver and Challenges

The trajectory of the Biktarvy market is defined by an intersection of drivers and challenges that result from technological advances in HIV therapy, economic determinants affecting drug pricing and availability, and the changing regulatory environment that defines pharmaceutical approvals and guidelines. These dynamics are essential for stakeholders to effectively navigate the market and for individuals living with HIV to obtain best-in-class care.

The factors responsible for driving the Biktarvy market include:

1. High Efficacy and Tolerability: Biktarvy's proven high viral suppression rates and good safety profile are key drivers of its commercial success. Clinical trial and real-world evidence all demonstrate its ability to suppress HIV with fewer side effects, and so it is a first choice for both treatment-naive patients and treatment-experienced patients. Its robust clinical profile favors its prescription by clinicians.

2. Convenient Once-Daily Single-Tablet Regimen: The ease of once-daily single-tablet therapy greatly enhances treatment adherence. For those with a chronic illness such as HIV, pill burden reduction makes their daily life easier and more likely to maintain regular medication, resulting in improved virologic response. This ease is one of the key reasons Biktarvy is so well received.

3. Strong Recommendation in Treatment Guidelines: Most HIV treatment guidelines globally recommend INSTI-based regimens, such as Biktarvy, as the first-line therapy of choice. These recommendations, supported by strong clinical evidence, lead to the use of Biktarvy by healthcare providers as a safe and effective first-line treatment for the majority of individuals with HIV.

4. Ongoing Innovation in HIV Treatment: Ongoing research and development in the HIV sector lend support to success stories of medications such as Biktarvy. Ongoing developments in antiretroviral drugs, aiming for increased efficacy, lower toxicity, and easier convenience, push the market toward newer and superior treatment alternatives. Biktarvy is one such development, aided by the advances in INSTI development.

5. Increased Awareness and Access to HIV Treatment: Global efforts to increase awareness of HIV, increase testing, and enhance access to treatment drive the expansion of the overall HIV drug market, including Biktarvy. As more individuals become diagnosed and connected to care, demand for effective antiretroviral therapies such as Biktarvy continues to increase.

Challenges in the Biktarvy market are:

1. Competition from Other Antiretroviral Therapies: The market for HIV treatment is competitive, with a number of other effective antiretroviral regimens, including other single-tablet regimens and new long-acting injectable therapies. This competition can restrict Biktarvy's market share and impose pricing pressures as manufacturers compete for patient preference and payer coverage.

2. Pricing and Reimbursement Concerns: The affordability of newer antiretroviral agents such as Biktarvy may be problematic, especially where there are constraints in resources or limited insurance cover. Favorable pricing and proper reimbursement policies that are strong must be negotiated so that market access is sustained and widespread use of Biktarvy is enabled.

3. Risk for Long-Term Side Effects and Resistance: Though Biktarvy has a benign safety profile, the risk of long-term side effects, including some that will not be easily recognized, cannot be eliminated. Moreover, despite the high resistance barrier of Biktarvy, drug resistance, which can evolve over time, is a possibility with any antiretroviral regimen, possibly curtailing its long-term efficacy in certain patients.

The Biktarvy market is fueled by its high efficacy, tolerability, convenient presentation, and favorable positioning in treatment guidelines, within a backdrop of continuous innovation and expanding access to HIV care. But it has challenges posed by competition, price and reimbursement complexities, and long-term side effects or resistance risks. Managing these drivers and challenges will be essential for Biktarvy in order to preserve its market leadership and remain an essential part of HIV treatment.

List of Biktarvy Companies

  • Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, Biktarvy companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the Biktarvy companies profiled in this report include:
  • Gilead Sciences
  • ABACUS MEDICINE
  • Hetero Drugs
  • Gador
  • BMODESTO

Biktarvy Market by Segment

The study includes a forecast for the global Biktarvy market by type, application, and region.

Biktarvy Market by Type [Value from 2019 to 2031]:

  • Brand Drugs
  • Generic Drugs

Biktarvy Market by Application [Value from 2019 to 2031]:

  • Hospitals
  • Retail Pharmacy
  • Others

Biktarvy Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Biktarvy Market

The Biktarvy market, a major HIV treatment segment worldwide, keeps growing in major geographies. Trends are influenced by drivers like growing adoption rates, competition from established and emerging antiretroviral therapies, pricing trends, and regulatory regimes. Gilead Sciences' Biktarvy, a once-daily, single-tablet regimen, has become a popular treatment because of its efficacy, safety profile, and convenience. Yet, market conditions differ significantly between countries, shaped by local healthcare systems, economic conditions, and HIV prevalence. It is important for stakeholders in the pharmaceutical sector and people living with HIV to understand these regional differences.

  • United States: Biktarvy enjoys robust market leadership in the US, fueled by strong demand and favorable reimbursement. Sales continue to increase, with a 7% year-on-year increase seen in the first quarter of 2025, contributing largely to Gilead's overall revenues. Although long-acting injectables such as Cabenuva represent competitive pressure, Biktarvy's established track record of efficacy and the convenience of a once-daily oral regimen guarantee its continued solid standing. Recent price revisions have taken place, demonstrating a balance between revenue generation and market access for Gilead.
  • China: Data on recent developments specifically for Biktarvy in China are sparse in the available search results. The overall Chinese pharmaceutical market, though, is seeing growth in traditional and specialty pharmaceuticals. Single-tablet regimens are becoming the norm for HIV, with branded therapies such as Biktarvy gaining strong share in the HIV segment. The overall pharmaceutical trend suggests a growing market for innovative treatments, which could positively impact Biktarvy's future trajectory in the region.
  • Germany: There are no specific recent developments on Biktarvy in Germany set out in the search results given. Nevertheless, Germany is a major market across Europe, and trends in other large European markets, including attention to single-tablet regimens and the effect of pricing and reimbursement policy, are likely applicable. The general European market will experience competitive prices as a result of policy action, which might influence the market dynamics of Biktarvy in Germany.
  • India: The search results do not yield particular recent updates on Biktarvy in India. The Indian pharma industry is, however, interested in bolstering its infrastructure to be a world leader. The overall antiviral drug market is growing, led by the rise in viral disease prevalence. As much as Biktarvy is an important global product, its particular market trends in India would be determined by local prices, access initiatives, and the availability of generic antiretrovirals.
  • Japan: Recent data suggest that Biktarvy is approved and on the market in Japan. This evidence has been presented at international meetings by Gilead, highlighting the safety and efficacy of Biktarvy across a range of patient subgroups. Japan, as with other developed countries, would prefer effective, convenient HIV treatment, which would play in the favor of Biktarvy. Market conditions would be shaped by the healthcare system and regulation in Japan.

Features of the Global Biktarvy Market

  • Market Size Estimates: Biktarvy market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Biktarvy market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Biktarvy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the Biktarvy market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Biktarvy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the Biktarvy market by type (brand drugs and generic drugs), application (hospitals, retail pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Biktarvy Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Brand Drugs: Trends and Forecast (2019-2031)
  • 4.4 Generic Drugs: Trends and Forecast (2019-2031)

5. Global Biktarvy Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Hospitals: Trends and Forecast (2019-2031)
  • 5.4 Retail Pharmacy: Trends and Forecast (2019-2031)
  • 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Biktarvy Market by Region

7. North American Biktarvy Market

  • 7.1 Overview
  • 7.2 North American Biktarvy Market by Type
  • 7.3 North American Biktarvy Market by Application
  • 7.4 United States Biktarvy Market
  • 7.5 Mexican Biktarvy Market
  • 7.6 Canadian Biktarvy Market

8. European Biktarvy Market

  • 8.1 Overview
  • 8.2 European Biktarvy Market by Type
  • 8.3 European Biktarvy Market by Application
  • 8.4 German Biktarvy Market
  • 8.5 French Biktarvy Market
  • 8.6 Spanish Biktarvy Market
  • 8.7 Italian Biktarvy Market
  • 8.8 United Kingdom Biktarvy Market

9. APAC Biktarvy Market

  • 9.1 Overview
  • 9.2 APAC Biktarvy Market by Type
  • 9.3 APAC Biktarvy Market by Application
  • 9.4 Japanese Biktarvy Market
  • 9.5 Indian Biktarvy Market
  • 9.6 Chinese Biktarvy Market
  • 9.7 South Korean Biktarvy Market
  • 9.8 Indonesian Biktarvy Market

10. ROW Biktarvy Market

  • 10.1 Overview
  • 10.2 ROW Biktarvy Market by Type
  • 10.3 ROW Biktarvy Market by Application
  • 10.4 Middle Eastern Biktarvy Market
  • 10.5 South American Biktarvy Market
  • 10.6 African Biktarvy Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Biktarvy Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Gilead Sciences
    • Company Overview
    • Biktarvy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 ABACUS MEDICINE
    • Company Overview
    • Biktarvy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Hetero Drugs
    • Company Overview
    • Biktarvy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Gador
    • Company Overview
    • Biktarvy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 BMODESTO
    • Company Overview
    • Biktarvy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Biktarvy Market
  • Figure 2.1: Usage of Biktarvy Market
  • Figure 2.2: Classification of the Global Biktarvy Market
  • Figure 2.3: Supply Chain of the Global Biktarvy Market
  • Figure 2.4: Driver and Challenges of the Biktarvy Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 4.1: Global Biktarvy Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Biktarvy Market ($B) by Type
  • Figure 4.3: Forecast for the Global Biktarvy Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Brand Drugs in the Global Biktarvy Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Generic Drugs in the Global Biktarvy Market (2019-2031)
  • Figure 5.1: Global Biktarvy Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Biktarvy Market ($B) by Application
  • Figure 5.3: Forecast for the Global Biktarvy Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Hospitals in the Global Biktarvy Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Retail Pharmacy in the Global Biktarvy Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Others in the Global Biktarvy Market (2019-2031)
  • Figure 6.1: Trends of the Global Biktarvy Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Biktarvy Market ($B) by Region (2025-2031)
  • Figure 7.1: Trends and Forecast for the North American Biktarvy Market (2019-2031)
  • Figure 7.2: North American Biktarvy Market by Type in 2019, 2024, and 2031
  • Figure 7.3: Trends of the North American Biktarvy Market ($B) by Type (2019-2024)
  • Figure 7.4: Forecast for the North American Biktarvy Market ($B) by Type (2025-2031)
  • Figure 7.5: North American Biktarvy Market by Application in 2019, 2024, and 2031
  • Figure 7.6: Trends of the North American Biktarvy Market ($B) by Application (2019-2024)
  • Figure 7.7: Forecast for the North American Biktarvy Market ($B) by Application (2025-2031)
  • Figure 7.8: Trends and Forecast for the United States Biktarvy Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Mexican Biktarvy Market ($B) (2019-2031)
  • Figure 7.10: Trends and Forecast for the Canadian Biktarvy Market ($B) (2019-2031)
  • Figure 8.1: Trends and Forecast for the European Biktarvy Market (2019-2031)
  • Figure 8.2: European Biktarvy Market by Type in 2019, 2024, and 2031
  • Figure 8.3: Trends of the European Biktarvy Market ($B) by Type (2019-2024)
  • Figure 8.4: Forecast for the European Biktarvy Market ($B) by Type (2025-2031)
  • Figure 8.5: European Biktarvy Market by Application in 2019, 2024, and 2031
  • Figure 8.6: Trends of the European Biktarvy Market ($B) by Application (2019-2024)
  • Figure 8.7: Forecast for the European Biktarvy Market ($B) by Application (2025-2031)
  • Figure 8.8: Trends and Forecast for the German Biktarvy Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the French Biktarvy Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Spanish Biktarvy Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the Italian Biktarvy Market ($B) (2019-2031)
  • Figure 8.12: Trends and Forecast for the United Kingdom Biktarvy Market ($B) (2019-2031)
  • Figure 9.1: Trends and Forecast for the APAC Biktarvy Market (2019-2031)
  • Figure 9.2: APAC Biktarvy Market by Type in 2019, 2024, and 2031
  • Figure 9.3: Trends of the APAC Biktarvy Market ($B) by Type (2019-2024)
  • Figure 9.4: Forecast for the APAC Biktarvy Market ($B) by Type (2025-2031)
  • Figure 9.5: APAC Biktarvy Market by Application in 2019, 2024, and 2031
  • Figure 9.6: Trends of the APAC Biktarvy Market ($B) by Application (2019-2024)
  • Figure 9.7: Forecast for the APAC Biktarvy Market ($B) by Application (2025-2031)
  • Figure 9.8: Trends and Forecast for the Japanese Biktarvy Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Indian Biktarvy Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Chinese Biktarvy Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the South Korean Biktarvy Market ($B) (2019-2031)
  • Figure 9.12: Trends and Forecast for the Indonesian Biktarvy Market ($B) (2019-2031)
  • Figure 10.1: Trends and Forecast for the ROW Biktarvy Market (2019-2031)
  • Figure 10.2: ROW Biktarvy Market by Type in 2019, 2024, and 2031
  • Figure 10.3: Trends of the ROW Biktarvy Market ($B) by Type (2019-2024)
  • Figure 10.4: Forecast for the ROW Biktarvy Market ($B) by Type (2025-2031)
  • Figure 10.5: ROW Biktarvy Market by Application in 2019, 2024, and 2031
  • Figure 10.6: Trends of the ROW Biktarvy Market ($B) by Application (2019-2024)
  • Figure 10.7: Forecast for the ROW Biktarvy Market ($B) by Application (2025-2031)
  • Figure 10.8: Trends and Forecast for the Middle Eastern Biktarvy Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the South American Biktarvy Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the African Biktarvy Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Biktarvy Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Biktarvy Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Biktarvy Market by Type
  • Figure 12.2: Growth Opportunities for the Global Biktarvy Market by Application
  • Figure 12.3: Growth Opportunities for the Global Biktarvy Market by Region
  • Figure 12.4: Emerging Trends in the Global Biktarvy Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Biktarvy Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Biktarvy Market by Region
  • Table 1.3: Global Biktarvy Market Parameters and Attributes
  • Table 3.1: Trends of the Global Biktarvy Market (2019-2024)
  • Table 3.2: Forecast for the Global Biktarvy Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Biktarvy Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Biktarvy Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Biktarvy Market (2025-2031)
  • Table 4.4: Trends of Brand Drugs in the Global Biktarvy Market (2019-2024)
  • Table 4.5: Forecast for Brand Drugs in the Global Biktarvy Market (2025-2031)
  • Table 4.6: Trends of Generic Drugs in the Global Biktarvy Market (2019-2024)
  • Table 4.7: Forecast for Generic Drugs in the Global Biktarvy Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Biktarvy Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Biktarvy Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Biktarvy Market (2025-2031)
  • Table 5.4: Trends of Hospitals in the Global Biktarvy Market (2019-2024)
  • Table 5.5: Forecast for Hospitals in the Global Biktarvy Market (2025-2031)
  • Table 5.6: Trends of Retail Pharmacy in the Global Biktarvy Market (2019-2024)
  • Table 5.7: Forecast for Retail Pharmacy in the Global Biktarvy Market (2025-2031)
  • Table 5.8: Trends of Others in the Global Biktarvy Market (2019-2024)
  • Table 5.9: Forecast for Others in the Global Biktarvy Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Biktarvy Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Biktarvy Market (2025-2031)
  • Table 7.1: Trends of the North American Biktarvy Market (2019-2024)
  • Table 7.2: Forecast for the North American Biktarvy Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Biktarvy Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Biktarvy Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Biktarvy Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Biktarvy Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Biktarvy Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Biktarvy Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Biktarvy Market (2019-2031)
  • Table 8.1: Trends of the European Biktarvy Market (2019-2024)
  • Table 8.2: Forecast for the European Biktarvy Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European Biktarvy Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European Biktarvy Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European Biktarvy Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European Biktarvy Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Biktarvy Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Biktarvy Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Biktarvy Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Biktarvy Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Biktarvy Market (2019-2031)
  • Table 9.1: Trends of the APAC Biktarvy Market (2019-2024)
  • Table 9.2: Forecast for the APAC Biktarvy Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Biktarvy Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Biktarvy Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Biktarvy Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Biktarvy Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Biktarvy Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Biktarvy Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Biktarvy Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Biktarvy Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Biktarvy Market (2019-2031)
  • Table 10.1: Trends of the ROW Biktarvy Market (2019-2024)
  • Table 10.2: Forecast for the ROW Biktarvy Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Biktarvy Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Biktarvy Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Biktarvy Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Biktarvy Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Biktarvy Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Biktarvy Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Biktarvy Market (2019-2031)
  • Table 11.1: Product Mapping of Biktarvy Suppliers Based on Segments
  • Table 11.2: Operational Integration of Biktarvy Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Biktarvy Revenue
  • Table 12.1: New Product Launches by Major Biktarvy Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Biktarvy Market